AstraZeneca CICC Medical Industry Fund
VC Fund
Beijing, China
AstraZeneca CICC Medical Industry Fund is a joint venture between AstraZeneca and CICC Capital.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries AstraZeneca CICC Medical Industry Fund invests in
Stages AstraZeneca CICC Medical Industry Fund invests in
Countries AstraZeneca CICC Medical Industry Fund invests in
Investment Focus
Industry
- Medical 7 (44%)
- Biotechnology 7 (44%)
- Health Care 4 (25%)
- Biopharma 3 (19%)
- Medical Device 3 (19%)
Stage
- Series A 4 (25%)
- Series B 3 (19%)
- Seed 2 (13%)
- Series D 2 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Syneron
|
Syneron was founded by Sinovation Ventures and is dedicated to using artificial intelligence and biotechnology to address two significant global challenges: the efficient development of novel biological therapies and the low-carbon manufacture of biochemicals. | $100M / Series A / Dec 11, 2025 | |
SonoSilicon
|
SonoSilicon researches on medical-grade micro-on-chip ultrasound systems and chip design and promotes the medical device industry. | Seed / Dec 11, 2025 | |
New Radiomedicine Technology
|
Chengdu New Radiomedicine Technology Co.,Ltd. is a Chinese medical isotopes provider. Our business covers research, manufacture and sales for medical isotopes and products. We provide services for malignant tumor diagnosis and treatments and radionuclides medicine technology support and consulting.In April 2016, the company was founded bythree co-founders experienced in radionuclides research and development. Jihui Qian, former President of Nuclear Power Institute of China (NPIC), former Deputy Director-General of International Atomic Energy Agency (IAEA); Maoliang Li, former Director of Chengdu Isotopes Institute of NPIC; and Jiming Cai, former Vice President of Sichuan Institute of Atomic Energy.The company is located in Western Airport Development District, Shuangliu, Chengdu, with an area of 71 Are, registered capital of 32.83 million CNY, and total investment of 300 million CNY. The project is listed as "Annual Key Investment Projects of Sichuan Province and Chengdu City in 2017, 2018 and 2019". At present, the company has over 80 employees, with more than 60 R&D specialists, including 1 academician of Chinese Academy of Engineering, 2 experts of Thousand Talent Project, 2 academic and technical leaders from Sichuan province, 10 researchers (associate researchers), and more than 20 people with middle or senior titles. Among them, there are 6 PhDs and over 30 graduates. The proportion of R&D staff has reached 70%, making CNRT the most innovative technology enterprise in the radiopharmaceutical industry in China. | $112.2M / Series D / Oct 09, 2025 | |
Glycogene
|
Glycogene specializing in directed evolution, and specialists in nucleic acid chemistry. | $13.9M / Series B / Aug 14, 2025 | |
Danking Pharmaceuticals
|
Danking Medicine is an innovation-driven drug developer. | $20.6M / Seed / Mar 03, 2025 | |
|
Danking Pharmaceuticals
|
Danking Medicine is an innovation-driven drug developer. | $20.6M / Seed / Mar 03, 2025 | |
Cholesgen
|
Cholesgen is a biopharmaceutical company dedicated to developing original innovative drugs. The company focuses on new disease targets based on biochemistry, disease biology, medicinal chemistry, and clinical translational medicine. | $13.8M / Series A / Feb 21, 2025 | |
|
Cholesgen
|
Cholesgen is a biopharmaceutical company dedicated to developing original innovative drugs. The company focuses on new disease targets based on biochemistry, disease biology, medicinal chemistry, and clinical translational medicine. | $13.8M / Series A / Feb 21, 2025 | |
bio Genous
|
Bozhen Bio is committed to providing standardized and modular organoid products and technical support for biomedical scientific research. | Series A / Dec 31, 2024 | |
Etern
|
Etern is developing small molecule drugs for protein liquid-liquid phase separation, using the LLPS platform for AI-enabled target discovery, high-throughput screening, and optimization. This could open new treatment strategies for major diseases. | Series B / Apr 01, 2024 | |
| See all 16 investments → | |||
Co-Investors
Pan-Lin Capital
4 deals together
AstraZeneca Pharmaceutical
2 deals together
Guofang Innovation
2 deals together
HSG
2 deals together
Kaitai Capital
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does AstraZeneca CICC Medical Industry Fund invest in?
AstraZeneca CICC Medical Industry Fund invests primarily in Medical, Biotechnology and Health Care startups, most often at Series A and Series B stage. Most of the 16 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did AstraZeneca CICC Medical Industry Fund last invest?
The most recent investment recorded for AstraZeneca CICC Medical Industry Fund closed in Dec 2025. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
